Orange Biomed Reveals Home A1c Test in U.S.

Orange Biomed, a diabetes management tech startup, has launched its OBM rapid A1c test in the U.S.
 
OBM rapid A1c, according to the company, is the world’s first glycated hemoglobin analyzer that uses single-cell analysis of red blood cells.
 
“Current technologies are likely to produce inaccurate A1c results disproportionately more for non-white patients due to hemoglobin variants,” Orange Biomed co-founder Yeaseul Park told the press. “Hemoglobin variants are more common in patients with African, South and Southeast Asian, and Mediterranean ancestry. Inaccurate results can delay diabetes diagnosis and serious long-term health damage. We invented a new method of A1c testing, free from hemoglobin variant interference, to facilitate earlier detection and management of diabetes across all patient populations.”
 
Park continued, “OBM rapid A1c is a portable, guided, five-minute test requiring only a single drop of blood to produce accurate results. By seamlessly integrating lab-level technology into portable devices, we seek to make healthcare more accessible, accurate, and affordable for everyone.”
 
Orange Biomed surpassed $2 million in pre-series A funding rounds. OBM rapid A1c is undergoing global studies with Asan Medical Center and the company said it is seeking U.S. Food and Drug Administration (FDA) clearance within a year.